Roth Capital Resumes Coverage on NovaBay Pharmaceuticals (NBY) at Buy
Tweet
Share
E-mailGet Alerts NBY Hot Sheet
Price: $1.95 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Roth Capital resumes coverage on NovaBay Pharmaceuticals (NYSE: NBY) with a Buy. PT $3.50.
For an analyst ratings summary and ratings history on NovaBay Pharmaceuticals click here. For more ratings news on NovaBay Pharmaceuticals click here.
Shares of NovaBay Pharmaceuticals closed at $1.28 yesterday.
For an analyst ratings summary and ratings history on NovaBay Pharmaceuticals click here. For more ratings news on NovaBay Pharmaceuticals click here.
Shares of NovaBay Pharmaceuticals closed at $1.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts Aditya Birla Real Estate (ABREL:IN) at Buy
- ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
